Target family: Other immune checkpoint proteins (type: other_protein)
Target: programmed cell death 1 (CD279)

Ligand: AUNP-12 (Peptide)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.140000343322754 pEC50
Reference (Patent): Immunosuppression modulating compounds

Ligand: cadonilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China NMPA (2022)
Primary target: yes
Median affinity: 10.289999961853027 pEC50
Reference (Journal): Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity.
Published in: MAbs

Ligand: cemiplimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: yes
Median affinity: 8.210000038146973 pKd
Reference (Journal): Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice.
Published in: Mol Cancer Ther

Ligand: cemiplimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: no
Median affinity: 8.130000114440918 pKd
Reference (Journal): Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice.
Published in: Mol Cancer Ther

Ligand: cemiplimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: yes
Median affinity: 9.199999809265137 pKd
Reference (Journal): Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice.
Published in: Mol Cancer Ther

Ligand: cemiplimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: no
Median affinity: 9.279999732971191 pKd
Reference (Journal): Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice.
Published in: Mol Cancer Ther

Ligand: dostarlimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA & FDA (2021)
Primary target: yes
Median affinity:  -
Reference (Journal): Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Published in: JAMA Oncol

Ligand: ivonescimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies
Published in: J Immunother Cancer

Ligand: nivolumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: yes
Median affinity: 9.140000343322754 pKd
Reference (Patent): Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics.

Ligand: nivolumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: yes
Median affinity: 9.140000343322754 pKd
Reference (Journal): Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
Published in: Curr Opin Investig Drugs

Ligand: nivolumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: yes
Median affinity: 9.140000343322754 pKd
Reference (Journal): Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Published in: Cancer Control

Ligand: pembrolizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2014), EMA (2015)
Primary target: yes
Median affinity: 10 pKd
Reference (Patent): Antibodies to human programmed death receptor PD-1.

Ligand: penpulimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China (2021)
Primary target: no
Median affinity: 10.229999542236328 pKd
Reference (Journal): Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events.
Published in: Front Immunol

Ligand: programmed cell death 1 ligand 1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: prolgolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.720000267028809 pKd
Reference (Patent): Anti-PD-1 antibodies, method for producing same and method for using same

Ligand: prolgolimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 12 pKd
Reference (Patent): Anti-PD-1 antibodies, method for producing same and method for using same

Ligand: retifanlimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 8.819999694824219 pKd
Reference (Patent): Pd-1-binding molecules and methods use thereof

Ligand: retifanlimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 8.34000015258789 pKd
Reference (Patent): Pd-1-binding molecules and methods use thereof

Ligand: sintilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China (2018)
Primary target: no
Median affinity: 9.350000381469727 pKd
Reference (Journal): Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
Published in: Antibody Therapeutics

Ligand: sintilimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China (2018)
Primary target: yes
Median affinity: 9.600000381469727 pKd
Reference (Journal): Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer
Published in: Antibody Therapeutics

Ligand: spartalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9.699999809265137 pKd
Reference (Patent): Antibody molecules to PD-1 and uses thereof

Ligand: tislelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China (2019), EMA (2023), FDA (2024)
Primary target: yes
Median affinity: 9.819999694824219 pKd
Reference (Webpage): A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.

Ligand: toripalimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 8.920000076293945 pKi
Reference (Journal): Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Published in: Acta Pharmacol Sin

Ligand: toripalimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 8.680000305175781 pKd
Reference (Journal): Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Published in: Acta Pharmacol Sin

Ligand: toripalimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2023)
Primary target: no
Median affinity: 7.679999828338623 pEC50
Reference (Journal): Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.
Published in: Acta Pharmacol Sin

Ligand: zimberelimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: China (2021)
Primary target: no
Median affinity: 10.760000228881836 pKd
Reference (Journal): Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer.
Published in: Front Oncol